LS301-IT for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new imaging agent, LS301-IT, to evaluate its effectiveness and safety for people with early-stage lung cancer. Participants will receive a dose of this agent before specific lung surgeries. The trial targets individuals with confirmed or highly suspected lung cancer who are scheduled for surgery. As a Phase 2 trial, the research measures the treatment's effectiveness in an initial, smaller group of people.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that LS301-IT is likely to be safe for humans?
Research has shown that LS301-IT, a new imaging agent used during lung cancer surgery, has been safe in earlier studies. In past research, LS301-IT was tested on patients, and the results were positive. Patients handled the treatment well, and no serious side effects occurred. This imaging agent works by directly targeting cancer cells, helping surgeons see and remove tumors more effectively. Since the current study is in Phase 2, LS301-IT has already demonstrated some safety in earlier trials. While every treatment carries potential risks, previous data suggest that LS301-IT is generally well-tolerated in people.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about LS301-IT for lung cancer because it introduces a novel mechanism of action compared to standard treatments like chemotherapy and targeted therapies. Unlike these options, LS301-IT is designed to be administered directly into the tumor, potentially enhancing its ability to attack and shrink the cancer cells more effectively. This targeted delivery method may result in fewer side effects and a more efficient response in combating the tumor, offering hope for improved outcomes in lung cancer treatment.
What evidence suggests that LS301-IT might be an effective treatment for lung cancer?
Research has shown that LS301-IT, the treatment under study in this trial, is a promising option for lung cancer. In earlier studies, LS301-IT helped surgeons see cancerous tissues more clearly during surgery. This special imaging agent makes tumors glow, aiding doctors in removing them more accurately. Initial findings also showed that LS301-IT is safe to use, with no major safety concerns reported. While researchers continue to collect more data, these early results suggest that LS301-IT could improve surgery outcomes for patients with non-small cell lung cancer.34678
Who Is on the Research Team?
Robert Honigberg, MD
Principal Investigator
Integro Theranostics
Are You a Good Fit for This Trial?
This trial is for individuals with Stage I-II non-small cell lung cancer (NSCLC) who are scheduled for surgical removal of the cancer using thoracoscopy and VATS or RATS techniques. Specific eligibility criteria details were not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of LS301-IT administered by intravenous infusion for fluorescence imaging during lung cancer resection surgery
Follow-up
Participants are monitored for safety and effectiveness after treatment, including the incidence of adverse events
What Are the Treatments Tested in This Trial?
Interventions
- LS301-IT
Trial Overview
The study tests a single dose of LS301-IT, an imaging agent given through IV to help surgeons see cancerous tissue during minimally invasive lung surgery. The goal is to assess how well it works and its safety.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Integro Theranostics
Lead Sponsor
Citations
NCT07276789 | Phase 2, Open-Label, Multicenter Study to ...
The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent ...
Promising Phase 1b Lung Cancer Surgery Clinical Trial ...
Results indicate safety and preliminary efficacy of LS301 for intraoperative cancer visualization. SAINT LOUIS, MO, UNITED STATES, September ...
Study Details | NCT06713564 | A Single Dose, Open-Label ...
The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of LS301-IT, a novel fluorescence imaging agent developed ...
Integro Theranostics announces positive Phase 1b clinical ...
Lung cancer surgery study results for proprietary tumor-targeting agent, CXL (formerly known as LS301), shows promising preliminary safety ...
LS301-IT Imaging for Lung Cancer · Info for Participants
Trial Overview The study tests LS301-IT, a new imaging agent given by IV before surgery. It's designed to help surgeons see the cancer better during operation.
Study Details | NCT06713564 | A Single Dose, Open-Label ...
The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of LS301-IT, a novel fluorescence imaging agent developed ...
A Single Dose, Open-Label, Dose-escalation Study of the ...
The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of LS301-IT, a novel fluorescence imaging ...
Science
LS301 is a stable molecule that directly targets cancer cells. It selectively binds to an activated protein that is uniquely expressed by cancer cells.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.